Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

Tom Baker Cancer Centre, Calgary, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:4City/State/Province:Calgary
Treatments:ChemotherapyHospital:Tom Baker Cancer Centre
Drugs:Journal:Link
Date:Jul 2005

Description:

Patients: This Phase II trial involved 10 patients with malignant gliomas. Seven had glioblastoma multiforme, and 3 had anaplastic astrocytomas. Seven patients were men, and three were women. All patients received radiotherapy before treatment, and one received prior chemotherapy.

Treatment: The treatment consisted of one chemotherapeutic agent: SarCNU.

Toxicity: Grade 3-4 toxicities included: granulocytopenia, leukopenia, thrombocytopenia, febrile neutropenia, and anemia.

Results: There were no complete or partial responses. The authors discontinued the study because pulmonary function deteriorated in three patients. The authors concluded, "Despite promising preclinical data, SarCNU caused pulmonary toxicity in patients with recurrent malignant glioma and we plan no further studies in this indication."

Correspondence: Elizabeth Eisenhauer, MD




Back